MDT

97.95

+1.59%↑

A

146.2

-0.2%↓

VEEV

217.4

-4.81%↓

HQY

85.38

+2.97%↑

NEOG

9.18

-0.76%↓

MDT

97.95

+1.59%↑

A

146.2

-0.2%↓

VEEV

217.4

-4.81%↓

HQY

85.38

+2.97%↑

NEOG

9.18

-0.76%↓

MDT

97.95

+1.59%↑

A

146.2

-0.2%↓

VEEV

217.4

-4.81%↓

HQY

85.38

+2.97%↑

NEOG

9.18

-0.76%↓

MDT

97.95

+1.59%↑

A

146.2

-0.2%↓

VEEV

217.4

-4.81%↓

HQY

85.38

+2.97%↑

NEOG

9.18

-0.76%↓

MDT

97.95

+1.59%↑

A

146.2

-0.2%↓

VEEV

217.4

-4.81%↓

HQY

85.38

+2.97%↑

NEOG

9.18

-0.76%↓

Search

Celldex Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

26.69 2.69

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

25.47

Max

26.85

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-10M

-67M

Pelno marža

-7,753.425

Darbuotojai

186

EBITDA

-9.8M

-73M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+112.11% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-25

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

200M

1.7B

Ankstesnė atidarymo kaina

24

Ankstesnė uždarymo kaina

26.69

Naujienos nuotaikos

By Acuity

50%

50%

183 / 361 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-13 19:05; UTC

Pagrindinės rinkos jėgos

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

2026-01-13 23:41; UTC

Rinkos pokalbiai

Nikkei May Rise on Japan Election Hopes -- Market Talk

2026-01-13 23:41; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-13 23:33; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

2026-01-13 23:13; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

2026-01-13 23:10; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

2026-01-13 23:03; UTC

Rinkos pokalbiai

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

2026-01-13 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

2026-01-13 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-01-13 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

2026-01-13 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

2026-01-13 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

2026-01-13 21:15; UTC

Įsigijimai, susijungimai, perėmimai

VERSANT Completes Acquisition Of Free TV Networks >VSNT

2026-01-13 21:08; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

2026-01-13 20:39; UTC

Rinkos pokalbiai

Silver Settles at Another New High -- Market Talk

2026-01-13 20:21; UTC

Rinkos pokalbiai

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

2026-01-13 20:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

2026-01-13 19:08; UTC

Įsigijimai, susijungimai, perėmimai

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

2026-01-13 19:03; UTC

Uždarbis

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

2026-01-13 18:50; UTC

Uždarbis

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

2026-01-13 17:54; UTC

Rinkos pokalbiai

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

2026-01-13 17:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2026-01-13 17:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

2026-01-13 17:49; UTC

Rinkos pokalbiai

Analysts Call For Potential Record Ethanol Output -- Market Talk

2026-01-13 17:38; UTC

Rinkos pokalbiai

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

2026-01-13 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-13 17:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-13 17:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-01-13 17:19; UTC

Rinkos pokalbiai

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

2026-01-13 17:15; UTC

Rinkos pokalbiai

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

112.11% į viršų

12 mėnesių prognozė

Vidutinis 55 USD  112.11%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

9

Pirkti

0

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

183 / 361 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat